Application of soluble PD-L2 as SLE biomarker

Abstract

The invention discloses an application of soluble PD-L2 as an SLE biomarker, and particularly discloses an application of soluble PD-L2 as an SLE biomarker in preparation of an SLE diagnosis and treatment evaluation reagent, and a detection sample of the diagnosis and treatment evaluation reagent is serum. Meanwhile, the invention discloses application of the reagent group in preparation of an SLEdiagnosis and treatment evaluation reagent, the reagent group comprises a soluble PD-L2 detection reagent and complement C3 and C4 detection reagents, and the soluble PD-L2 level is positively correlated with the complement C3 and C4 levels. The detection kit is used for combined detection of soluble PD-L2 and complement C3 and C4 in a serum sample, can be effectively used for early diagnosis andprognosis evaluation of SLE diseases, provides a new approach for diagnosis and treatment of the SLE diseases, and has good clinical application prospects.

Description

technical field [0001] The invention belongs to the technical field of biological detection, and in particular relates to the application of soluble PD-L2 (sPD-L2) as an SLE biomarker. Background technique [0002] SLE is a rheumatic autoimmune disease, and its clinical manifestations can involve various organs and tissues in the whole body. It is a systemic and diffuse disease. SLE tends to occur in young women, usually 20-40 years old women of childbearing age. In the pathogenesis of SLE, autoimmune tolerance impairment, autoantibody production and inflammatory cell infiltration caused by excessive activation of lymphocytes are the main pathological damage mechanisms. In the immunopathological process of SLE, the B7 / CD28 family molecular signaling pathway plays an important role. It can not only initiate, enhance and maintain the immune response mediated by T and B lymphocytes by providing positive co-stimulatory signals, but also through Provides negative co-stimulatory...

AI Technical Summary

Problems solved by technology

[0005] The clinical manifestations of SLE are complex and diverse, the condition is repeated and changeable, and early diagnosis is difficult. Therefore, it is urgent to seek a new, specific and sensitive biomarker for the diagnosis and prognosis of SLE.

So far, there is no report on using serum sPD-L2 level as a biomarker for SLE disease

Images